On July 1, 2025, the 28th anniversary of Hong Kong’s return to the motherland, the list of FattaLab® new product experience officers was also announced today! As a benchmark company in Hong Kong’s technological innovation, Eieling Technology relies on the advantages of Hong Kong’s scientific and technological innovation platform, always focusing on the real needs of people with liver diseases and exploring more innovative possibilities for liver health solutions.
On May 27 this year, Eieling Technology successfully held the FattaLab® new product launch and the unveiling ceremony of”Innovative Application Scenario incubation Platform” and the “ELT+ Liver screening Alliance” in the Greater China region. This event is not only a high recognition of Eieling Technology’s technical strength, but also marks a new stage in the precise detection of liver diseases.
FattaLab: THE WORLD’S FIRST LIGHTWEIGHT FATTY LIVER INTELLIGENT ASSESSMENT SYSTEM
In recent years, the incidence of fatty liver has continued to rise and has become one of the most common chronic liver diseases. Against this background, Eieling Technology, relying on the Hong Kong Science and Technology Innovation Platform, launched the world’s first lightweight fatty liver intelligent assessment system – FattaLab®.
It is equipped with a human liver fat detection algorithm, which enables one-click detection and automatic analysis, and obtains quantitative results of fatty liver within 30 seconds. Intelligent reports can be obtained through the mobile APP, providing medical-grade, accurate data, greatly improving detection efficiency and accessibility.
FattaLab® provides a new solution for the accurate detection, screening, treatment, and follow-up management of fatty liver, significantly lowering the threshold for technology use, promoting the popularization of liver disease detection technology, and officially opening the era of health monitoring 3.0.
Multi-scenario application: improving the reach rate of high-risk groups
FattaLab® breaks through the limitations of traditional medical institutions and can cover non-medical scenarios such as gyms and insurance companies, further reaching more people at high risk of fatty liver disease. Through integration with multiple scenarios, FattaLab® provides patients with fatty liver with a more convenient early intervention and treatment approach, assists doctors in predicting the risk of chronic liver disease through accurate data, and enables more people to achieve data-driven health management.
FattaLab® Experience Officer Lineup Revealed
In order to further optimize product applicability and user experience, Eieling Technology has specially invited a number of scholars, liver disease experts, and investment professionals to serve as new product experience officers. At the important moment of the 28th anniversary of Hong Kong’s return to the motherland, Eieling Technology officially announced the first batch of experience officers (ranking in no particular order):
Prof. Christopher Chao, Vice President (Research and Innovation), The Hong Kong Polytechnic University
Mr Eric Or, Acting Chief Corporate Development Officer, Hong Kong Science & Technology Parks Corporation
Prof. Wai-Kay Seto, Department of Gastroenterology & Hepatology, Queen Mary Hospital, The University of Hong Kong
Mr. Patrick Lau, Deputy Executive Director of the Hong Kong Trade Development Council
Mr. Cai Qingsheng, Chairman of Guangzhou Doppler Electronic Technologies Co., Ltd.
Mr. Nixon Chung， Managing Director of Camloy International Limited, President of The Hong Kong Polytechnic University Shanghai Alumni Network
Mr. Zhong Yongxi, Chief China Representative of the Hong Kong Trade Development Council
Mr. Steve Zheng, Eieling Investor
Mr.Kelvin Wong， Director of Knowledge Transfer and Entrepreneurship Office
Sincerely thank the above experience officers for their strong support of Eieling Technology! Next, Eieling Technology will release new products one after another, and invite all experience officers to personally experience the advantages of FattaLab® in terms of performance, design, and usage, so as to obtain the most authentic and comprehensive experience, and thus make better product optimization.
In the future, Eieling Technology will continue to rely on Hong Kong’s unique advantage of “backed by the motherland and connected to the world” to continuously enhance the market competitiveness of its products. Together with industry partners and with users at the center, it will promote the continuous innovation of liver disease detection technology, so that more Chinese original medical technologies can benefit liver disease patients around the world and contribute to the optimization of the entire process of liver disease management.
